

108TH CONGRESS  
2D SESSION

**S. 1881**

---

---

**AMENDMENT**



***In the House of Representatives, U. S.,***

*March 10, 2004.*

*Resolved*, That the bill from the Senate (S. 1881) entitled “An Act to amend the Federal Food, Drug, and Cosmetic Act to make technical corrections relating to the amendments made by the Medical Device User Fee and Modernization Act of 2002, and for other purposes”, do pass with the following

**AMENDMENT:**

Strike out all after the enacting clause and insert:

1 ***SECTION 1. SHORT TITLE.***

2 *This Act may be cited as the “Medical Devices Tech-*  
3 *nical Corrections Act”.*

4 ***SEC. 2. TECHNICAL CORRECTIONS REGARDING PUBLIC LAW***

5 ***107-250.***

6 *(a) TITLE I; FEES RELATING TO MEDICAL DE-*  
7 *VICES.—Part 3 of subchapter C of chapter VII of the Fed-*  
8 *eral Food, Drug, and Cosmetic Act (21 U.S.C. 379i et seq.),*  
9 *as added by section 102 of Public Law 107-250 (116 Stat.*  
10 *1589), is amended—*

11 *(1) in section 737—*

1           (A) in paragraph (4)(B), by striking “and  
2           for which clinical data are generally necessary to  
3           provide a reasonable assurance of safety and ef-  
4           fectiveness” and inserting “and for which sub-  
5           stantial clinical data are necessary to provide a  
6           reasonable assurance of safety and effectiveness”;

7           (B) in paragraph (4)(D), by striking “man-  
8           ufacturing,”;

9           (C) in paragraph (5)(J), by striking “a  
10          premarket application” and all that follows and  
11          inserting “a premarket application or premarket  
12          report under section 515 or a premarket applica-  
13          tion under section 351 of the Public Health Serv-  
14          ice Act.”; and

15          (D) in paragraph (8), by striking “The  
16          term ‘affiliate’ means a business entity that has  
17          a relationship with a second business entity”  
18          and inserting “The term ‘affiliate’ means a busi-  
19          ness entity that has a relationship with a second  
20          business entity (whether domestic or inter-  
21          national)”;

22          (2) in section 738—

23                  (A) in subsection (a)(1)—

24                          (i) in subparagraph (A)—

1                   (I) in the matter preceding clause  
2                   (i) by striking “subsection (d),” and  
3                   inserting “subsections (d) and (e),”;

4                   (II) in clause (iv), by striking  
5                   “clause (i),” and all that follows and  
6                   inserting “clause (i).”; and

7                   (III) in clause (vii), by striking  
8                   “clause (i),” and all that follows and  
9                   inserting “clause (i), subject to any ad-  
10                  justment                  under                  subsection  
11                  (e)(2)(C)(ii).”; and

12                  (ii) in subparagraph (D), in each of  
13                  clauses (i) and (ii), by striking “applica-  
14                  tion” and inserting “application, report,”;

15                  (B) in subsection (d)(2)(B), beginning in  
16                  the second sentence, by striking “firms. which  
17                  show” and inserting “firms, which show”;

18                  (C) in subsection (e)—

19                   (i) in paragraph (1), by striking  
20                   “Where” and inserting “For fiscal year  
21                   2004 and each subsequent fiscal year,  
22                   where”; and

23                   (ii) in paragraph (2)—

24                   (I) in subparagraph (B), begin-  
25                   ning in the second sentence, by striking

1           *“firms. which show” and inserting*  
2           *“firms, which show”; and*

3                   *(II) in subparagraph (C)(i), by*  
4           *striking “Where” and inserting “For*  
5           *fiscal year 2004 and each subsequent*  
6           *fiscal year, where”;*

7           *(D) in subsection (f), by striking “for fil-*  
8           *ing”; and*

9           *(E) in subsection (h)(2)(B)—*

10                   *(i) in clause (ii), by redesignating sub-*  
11           *clauses (I) and (II) as items (aa) and (bb),*  
12           *respectively;*

13                   *(ii) by redesignating clauses (i) and*  
14           *(ii) as subclauses (I) and (II), respectively;*

15                   *(iii) by striking “The Secretary” and*  
16           *inserting the following:*

17                   *“(i) IN GENERAL.—The Secretary”;*  
18           *and*

19                   *(iv) by adding at the end the following:*

20                   *“(ii) MORE THAN 5 PERCENT.—To the*  
21           *extent such costs are more than 5 percent*  
22           *below the specified level in subparagraph*  
23           *(A)(ii), fees may not be collected under this*  
24           *section for that fiscal year.”.*

1       **(b) TITLE II; AMENDMENTS REGARDING REGULATION**  
2 **OF MEDICAL DEVICES.—**

3           **(1) INSPECTIONS BY ACCREDITED PERSONS.—**

4       *Section 704(g) of the Federal Food, Drug, and Cos-*  
5 *metic Act (21 U.S.C. 374(g)), as added by section 201*  
6 *of Public Law 107–250 (116 Stat. 1602), is*  
7 *amended—*

8           **(A)** *in paragraph (1), in the first sentence,*  
9 *by striking “conducting inspections” and all that*  
10 *follows and inserting “conducting inspections of*  
11 *establishments that manufacture, prepare, propa-*  
12 *gate, compound, or process class II or class III*  
13 *devices, which inspections are required under*  
14 *section 510(h) or are inspections of such estab-*  
15 *lishments required to register under section*  
16 *510(i).”;*

17           **(B)** *in paragraph (5)(B), in the first sen-*  
18 *tence, by striking “or poses” and all that follows*  
19 *through the period and inserting “poses a threat*  
20 *to public health, fails to act in a manner that*  
21 *is consistent with the purposes of this subsection,*  
22 *or where the Secretary determines that there is*  
23 *a financial conflict of interest in the relationship*  
24 *between the accredited person and the owner or*  
25 *operator of a device establishment that the ac-*

1           *credited person has inspected under this sub-*  
2           *section.”;*

3           *(C) in paragraph (6)(A)—*

4                 *(i) in clause (i), by striking “of the es-*  
5                 *tablishment pursuant to subsection (h) or*  
6                 *(i) of section 510” and inserting “described*  
7                 *in paragraph (1)”;*

8                 *(ii) in clause (ii)—*

9                         *(I) in the matter preceding sub-*  
10                        *clause (I)—*

11                                 *(aa) by striking “each in-*  
12                                *spection” and inserting “inspec-*  
13                                *tions”;* and

14                                 *(bb) by inserting “during a*  
15                                *2-year period” after “person”;*  
16                                and

17                                 *(II) in subclause (I), by striking*  
18                                *“such a person” and inserting “an ac-*  
19                                *credited person”;*

20                 *(iii) in clause (iii)—*

21                         *(I) in the matter preceding sub-*  
22                         *clause (I), by striking “and the fol-*  
23                         *lowing additional conditions are met:”*  
24                         *and inserting “and 1 or both of the fol-*  
25                         *lowing additional conditions are met.”;*



1                   (II) in subclause (I), by striking  
2                   “accredited” and all that follows  
3                   through the period and inserting “(ac-  
4                   credited under paragraph (2) and  
5                   identified under clause (ii)(II)) as a  
6                   person authorized to conduct such in-  
7                   spections of device establishments.”;  
8                   and

9                   (III) in subclause (II), by insert-  
10                  ing “or by a person accredited under  
11                  paragraph (2)” after “by the Sec-  
12                  retary”;

13               (iv) in clause (iv)(I)—

14               (I) in the first sentence—

15               (aa) by striking “the two im-  
16               mediately preceding inspections of  
17               the establishment” and inserting  
18               “inspections of the establishment  
19               during the previous 4 years”; and

20               (bb) by inserting “section”  
21               after “pursuant to”;

22               (II) in the third sentence—

23               (aa) by striking “the petition  
24               states a commercial reason for the  
25               waiver;” and

1                   (bb) by inserting “not” after

2                   “the Secretary has not determined

3                   that the public health would”; and

4                   (III) in the fourth sentence, by

5                   striking “granted until” and inserting

6                   “granted or deemed to be granted

7                   until”; and

8                   (v) in clause (iv)(II)—

9                   (I) by inserting “of a device estab-

10                  lishment required to register” after “to

11                  be conducted”; and

12                  (II) by inserting “section” after

13                  “pursuant to”;

14                  (D) in paragraph (6)(B)(iii)—

15                  (i) in the first sentence, by striking “,

16                  and data otherwise describing whether the

17                  establishment has consistently been in com-

18                  pliance with sections 501 and 502 and

19                  other” and inserting “and with other”; and

20                  (ii) in the second sentence—

21                  (I) by striking “inspections” and

22                  inserting “inspectional findings”; and

23                  (II) by inserting “relevant” after

24                  “together with all other”;

25                  (E) in paragraph (6)(B)(iv)—

1                   (i) by inserting “(I)” after “(iv)”; and

2                   (ii) by adding at the end the following:

3           “(II) If, during the two-year period following clear-  
4   ance under subparagraph (A), the Secretary determines  
5   that the device establishment is substantially not in compli-  
6   ance with this Act, the Secretary may, after notice and a  
7   written response, notify the establishment that the eligi-  
8   bility of the establishment for the inspections by accredited  
9   persons has been suspended.”;

10                   (F) in paragraph (6)(C)(ii), by striking “in  
11           accordance with section 510(h), or has not dur-  
12           ing such period been inspected pursuant to sec-  
13           tion 510(i), as applicable”;

14                   (G) in paragraph (10)(B)(iii), by striking  
15           “a reporting” and inserting “a report”; and

16                   (H) in paragraph (12)—

17                   (i) by striking subparagraph (A) and  
18                   inserting the following:

19                   “(A) the number of inspections conducted by ac-  
20           credited persons pursuant to this subsection and the  
21           number of inspections conducted by Federal employees  
22           pursuant to section 510(h) and of device establish-  
23           ments required to register under section 510(i);”;

24                   (ii) in subparagraph (E), by striking  
25                   “obtained by the Secretary” and all that

1 follows and inserting “obtained by the Sec-  
2 retary pursuant to inspections conducted by  
3 Federal employees;”.

4 (2) OTHER CORRECTIONS.—

5 (A) PROHIBITED ACTS.—Section 301(gg) of  
6 the Federal Food, Drug, and Cosmetic Act (21  
7 U.S.C. 331(gg)), as amended by section 201(d) of  
8 Public Law 107–250 (116 Stat. 1609), is amend-  
9 ed to read as follows:

10 “(gg) The knowing failure to comply with paragraph  
11 (7)(E) of section 704(g); the knowing inclusion by a person  
12 accredited under paragraph (2) of such section of false in-  
13 formation in an inspection report under paragraph (7)(A)  
14 of such section; or the knowing failure of such a person to  
15 include material facts in such a report.”.

16 (B) ELECTRONIC LABELING.—Section  
17 502(f) of the Federal Food, Drug, and Cosmetic  
18 Act (21 U.S.C. 352(f)), as amended by section  
19 206 of Public Law 107–250 (116 Stat. 1613), is  
20 amended, in the last sentence—

21 (i) by inserting “or by a health care  
22 professional and required labeling for in  
23 vitro diagnostic devices intended for use by  
24 health care professionals or in blood estab-  
25 lishments” after “in health care facilities”;

1                   (ii) by inserting a comma after  
2                   “means”;

3                   (iii) by striking “requirements of law  
4                   and, that” and inserting “requirements of  
5                   law, and that”;

6                   (iv) by striking “the manufacturer af-  
7                   fords health care facilities the opportunity”  
8                   and inserting “the manufacturer affords  
9                   such users the opportunity”; and

10                   (v) by striking “the health care facil-  
11                   ity”.

12                   (c) *TITLE III; ADDITIONAL AMENDMENTS.*—

13                   (1) *EFFECTIVE DATE.*—Section 301(b) of Public  
14                   Law 107–250 (116 Stat. 1616), is amended by strik-  
15                   ing “18 months” and inserting “36 months”.

16                   (2) *PREMARKET NOTIFICATION.*—Section 510(o)  
17                   of the Federal Food, Drug, and Cosmetic Act (21  
18                   U.S.C. 360(o)), as added by section 302(b) of Public  
19                   Law 107–250 (116 Stat. 1616), is amended—

20                   (A) in paragraph (1)(B), by striking “,  
21                   adulterated” and inserting “or adulterated”; and

22                   (B) in paragraph (2)—

23                   (i) in subparagraph (B), by striking “,  
24                   adulterated” and inserting “or adulter-  
25                   ated”; and

1                   (ii) in subparagraph (E), by striking  
2                   “semicritical” and inserting “semi-critical”.

3           (d) MISCELLANEOUS CORRECTIONS.—

4                   (1) CERTAIN AMENDMENTS TO SECTION 515.—

5                           (A) IN GENERAL.—

6                                   (i) TECHNICAL CORRECTION.—Section  
7                                   515(c) of the Federal Food, Drug, and Cos-  
8                                   metic Act (21 U.S.C. 360e(c)), as amended  
9                                   by sections 209 and 302(c)(2)(A) of Public  
10                                  Law 107–250 (116 Stat. 1613, 1618), is  
11                                  amended by redesignating paragraph (3)  
12                                  (as added by section 209 of such Public  
13                                  Law) as paragraph (4).

14                                  (ii) MODULAR REVIEW.—Section  
15                                  515(c)(4)(B) of the Federal Food, Drug, and  
16                                  Cosmetic Act (21 U.S.C. 360e(c)(4)(B)) is  
17                                  amended by striking “unless an issue of  
18                                  safety” and inserting “unless a significant  
19                                  issue of safety”.

20                                  (B) CONFORMING AMENDMENT.—Section  
21                                  210 of Public Law 107–250 (116 Stat. 1614) is  
22                                  amended by striking “, as amended” and all that  
23                                  follows through “by adding” and inserting “is  
24                                  amended in paragraph (3), as redesignated by  
25                                  section 302(c)(2)(A) of this Act, by adding”.

1           (2) *CERTAIN AMENDMENTS TO SECTION 738.*—

2           (A) *IN GENERAL.*—Section 738(a) of the  
3 *Federal Food, Drug, and Cosmetic Act* (21  
4 *U.S.C. 379j(a)*), as amended by subsection (a), is  
5 amended—

6           (i) in the matter preceding paragraph

7           (1)—

8           (I) by striking “(a) *TYPES OF*  
9 *FEES.*—Beginning on” and inserting  
10 *the following:*

11       “(a) *TYPES OF FEES.*—

12       “(1) *IN GENERAL.*—Beginning on”; and

13       (II) by striking “this section as  
14 *follows:*” and inserting “this section.”;  
15 *and*

16       (ii) by striking “(1) *PREMARKET AP-*  
17 *PLICATION,*” and inserting the following:

18       “(2) *PREMARKET APPLICATION,*”.

19       (B) *CONFORMING AMENDMENTS.*—Section  
20 *738 of the Federal Food, Drug, and Cosmetic Act*  
21 *(21 U.S.C. 379j)*, as amended by subparagraph  
22 (A), is amended—

23       (i) in subsection (d)(1), in the last sen-  
24 *tence, by striking “subsection (a)(1)(A)”*  
25 *and inserting “subsection (a)(2)(A)”;*

1                   (ii) in subsection (e)(1), by striking  
2                   “subsection (a)(1)(A)(vii)” and inserting  
3                   “subsection (a)(2)(A)(vii)”;

4                   (iii) in subsection (e)(2)(C)—

5                   (I) in each of clauses (i) and (ii),  
6                   by striking “subsection (a)(1)(A)(vii)”  
7                   and inserting “subsection  
8                   (a)(2)(A)(vii)”; and

9                   (II) in clause (ii), by striking  
10                  “subsection (a)(1)(A)(i)” and inserting  
11                  “subsection (a)(2)(A)(i)”; and

12                  (iv) in subsection (j), by striking “sub-  
13                  section (a)(1)(D),” and inserting “sub-  
14                  section (a)(2)(D),”.

15                  (C) *ADDITIONAL CONFORMING AMEND-*  
16                  *MENT.—Section 102(b)(1) of Public Law 107–*  
17                  *250 (116 Stat. 1600) is amended, in the matter*  
18                  *preceding subparagraph (A), by striking “section*  
19                  *738(a)(1)(A)(ii)” and inserting “section*  
20                  *738(a)(2)(A)(ii)”.*

21                  (3) *PUBLIC LAW 107–250.—Public Law 107–250*  
22                  *is amended—*

23                         (A) in section 102(a) (116 Stat. 1589), by  
24                         striking “(21 U.S.C. 379F et seq.)” and inserting  
25                         “(21 U.S.C. 379f et seq.)”;



1                   (B) in section 102(b) (116 Stat. 1600)—

2                   (i) by striking paragraph (2);

3                   (ii) in paragraph (1), by redesignating  
4                   subparagraphs (A) and (B) as paragraphs  
5                   (1) and (2), respectively; and

6                   (iii) by striking:

7                   “(b) *FEE EXEMPTION FOR CERTAIN ENTITIES SUB-*  
8 *MITTING PREMARKET REPORTS.*—

9                   “(1) *IN GENERAL.*—A person submitting a pre-  
10 *market report*”and inserting:

11                   “(b) *FEE EXEMPTION FOR CERTAIN ENTITIES SUB-*  
12 *MITTING PREMARKET REPORTS.*—A person submitting a  
13 *premarket report*”; and

14                   (C) in section 212(b)(2) (116 Stat. 1614),  
15                   by striking “, such as phase IV trials,”.

16 **SEC. 3. REPORT ON BARRIERS TO AVAILABILITY OF DE-**  
17 **VICES INTENDED FOR CHILDREN.**

18                   Not later than 180 days after the date of enactment  
19 of this Act, the Secretary of Health and Human Services  
20 shall submit to the Committee on Health, Education, Labor,  
21 and Pensions of the Senate and the Committee on Energy  
22 and Commerce of the House of Representatives a report on  
23 the barriers to the availability of devices intended for the  
24 treatment or diagnosis of diseases and conditions that affect  
25 children. The report shall include any recommendations of

1 *the Secretary of Health and Human Services for changes*  
2 *to existing statutory authority, regulations, or agency pol-*  
3 *icy or practice to encourage the invention and development*  
4 *of such devices.*

Attest:

*Clerk.*